Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
Multiple sclerosis
demyelination
magnetic resonance imaging
myelin water imaging
quantitative MRI
spinal cord
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
23
3
2021
medline:
28
1
2022
entrez:
22
3
2021
Statut:
ppublish
Résumé
Myelin water imaging (MWI) was recently optimized to provide quantitative in vivo measurement of spinal cord myelin, which is critically involved in multiple sclerosis (MS) disability. To assess cervical cord myelin measurements in relapsing-remitting multiple sclerosis (RRMS) and progressive multiple sclerosis (ProgMS) participants and evaluate the correlation between myelin measures and clinical disability. We used MWI data from 35 RRMS, 30 ProgMS, and 28 healthy control (HC) participants collected at cord level C2/C3 on a 3 T magnetic resonance imaging (MRI) scanner. Myelin heterogeneity index (MHI), a measurement of myelin variability, was calculated for whole cervical cord, global white matter, dorsal column, lateral and ventral funiculi. Correlations were assessed between MHI and Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9HPT), timed 25-foot walk, and disease duration. In various regions of the cervical cord, ProgMS MHI was higher compared to HC (between 9.5% and 31%, Myelin abnormalities within clinically eloquent areas are related to clinical disability. MWI metrics have a potential role for monitoring subclinical disease progression and adjudicating treatment efficacy for new therapies targeting ProgMS.
Sections du résumé
BACKGROUND
Myelin water imaging (MWI) was recently optimized to provide quantitative in vivo measurement of spinal cord myelin, which is critically involved in multiple sclerosis (MS) disability.
OBJECTIVE
To assess cervical cord myelin measurements in relapsing-remitting multiple sclerosis (RRMS) and progressive multiple sclerosis (ProgMS) participants and evaluate the correlation between myelin measures and clinical disability.
METHODS
We used MWI data from 35 RRMS, 30 ProgMS, and 28 healthy control (HC) participants collected at cord level C2/C3 on a 3 T magnetic resonance imaging (MRI) scanner. Myelin heterogeneity index (MHI), a measurement of myelin variability, was calculated for whole cervical cord, global white matter, dorsal column, lateral and ventral funiculi. Correlations were assessed between MHI and Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9HPT), timed 25-foot walk, and disease duration.
RESULTS
In various regions of the cervical cord, ProgMS MHI was higher compared to HC (between 9.5% and 31%,
CONCLUSION
Myelin abnormalities within clinically eloquent areas are related to clinical disability. MWI metrics have a potential role for monitoring subclinical disease progression and adjudicating treatment efficacy for new therapies targeting ProgMS.
Identifiants
pubmed: 33749378
doi: 10.1177/13524585211001780
pmc: PMC8597183
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2191-2198Références
Neuroimage. 2014 Jan 1;84:1070-81
pubmed: 23685159
Magn Reson Med. 2012 Jun;67(6):1803-14
pubmed: 22012743
Neuroimage Clin. 2019;23:101896
pubmed: 31276928
Sci Rep. 2021 Jan 11;11(1):269
pubmed: 33431990
Magn Reson Med. 1994 Jun;31(6):673-7
pubmed: 8057820
Mult Scler. 2006 Dec;12(6):747-53
pubmed: 17263002
AJNR Am J Neuroradiol. 2011 Jan;32(1):85-91
pubmed: 20947644
Neuroimage. 2017 Jan 15;145(Pt A):24-43
pubmed: 27720818
J Magn Reson Imaging. 2015 Mar;41(3):700-7
pubmed: 24578324
Neuroimage Clin. 2017 Jun 16;16:17-22
pubmed: 28725551
NMR Biomed. 2002 Nov-Dec;15(7-8):435-55
pubmed: 12489094
Brain. 1999 May;122 ( Pt 5):871-82
pubmed: 10355672
Brain Plast. 2016 Dec 21;2(1):71-91
pubmed: 29765849
J Magn Reson Imaging. 2011 Mar;33(3):713-8
pubmed: 21563257
Neurology. 2013 Jun 11;80(24):2201-9
pubmed: 23667060
ILAR J. 2007;48(4):396-410
pubmed: 17712225
J Neuroimaging. 2000 Apr;10(2):67-72
pubmed: 10800258
J Neuroimaging. 2020 Mar;30(2):205-211
pubmed: 31762132
PLoS One. 2016 Feb 25;11(2):e0150215
pubmed: 26913900
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neuroimage. 2012 Oct 15;63(1):533-9
pubmed: 22776448
NMR Biomed. 2001 Apr;14(2):57-64
pubmed: 11320533
Magn Reson Med. 2017 Oct;78(4):1482-1487
pubmed: 28940333
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 2019 Mar 1;142(3):633-646
pubmed: 30715195
Neuroimage Clin. 2015 Oct 03;9:574-80
pubmed: 26594633
J Comp Neurol. 2015 Oct 1;523(14):2138-60
pubmed: 25845707
J Neurosci Res. 2006 Feb 15;83(3):392-402
pubmed: 16397901
Mol Psychiatry. 2003 Sep;8(9):811-20
pubmed: 12931208
Alzheimers Res Ther. 2020 Sep 10;12(1):105
pubmed: 32912337
Front Neurosci. 2018 Nov 21;12:854
pubmed: 30519158
J Magn Reson Imaging. 2013 Dec;38(6):1445-53
pubmed: 23553991
Lancet Neurol. 2019 Feb;18(2):185-197
pubmed: 30663608
Neuroimage. 2018 Jan 15;165:170-179
pubmed: 29061527
Neuroimage. 2006 Aug 15;32(2):637-42
pubmed: 16677833